IKEMA: Carfilzomib and dexamethasone plus isatuximab for r/r multiple myeloma

Bookmark and Share
Published: 25 Jun 2020
Views: 621
Prof Philippe Moreau - University of Nantes, Nantes, France

Prof Philippe Moreau speaks to ecancer in an online interview for the virtual EHA 2020 meeting.

He discusses the IKEMA trial which looked at carfilzomib and dexamethasone vs carfilzomib and dexamethasone plus isatuximab in relapsed/refractory multiple myeloma.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.